Opioid-induced hyperalgesia: A review of epidemiology, mechanisms and management

Singapore Medical Journal

Volumn 53, Issue 5, 2012, Pages 357-360

  Low, Yinghui ^a   Clarke, Collin F ^b   Huh, Billy K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Hyperalgesia; Opioids; Tolerance; Withdrawal

Indexed keywords

CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXMEDETOMIDINE; DEXTROMETHORPHAN; FENTANYL; KETAMINE; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; NEUROKININ 1 RECEPTOR; OPIATE; OPIATE RECEPTOR; PROPOFOL; REMIFENTANIL; SEROTONIN 3 RECEPTOR; SUBSTANCE P;

ALLODYNIA; ARTICLE; DIFFUSE NOXIOUS INHIBITORY CONTROL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; HYPERALGESIA; LOW DRUG DOSE; OPIOID INDUCED HYPERALGESIA; PREVALENCE;

ANALGESICS, OPIOID; DRUG TOLERANCE; HUMANS; HYPERALGESIA; PAIN MEASUREMENT;

EID: 84865105342     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006; 104:570-587.
2. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24:479-96.
3. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol 2007; 21:65-83.
4. Simonnet G, Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport 2003; 14:1-7.
5. Martin JE, Inglis J. Pain tolerance and narcotic addiction. Br J Soc Clin Psychol 1965; 4:224-9.
6. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63:139-46.
7. Vanderah TW, Ossipov MH, Lai J, et al. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 2001; 92:5-9.
8. Zylicz Z, Twycross R. Opioid-induced hyperalgesia may be more frequent than previously thought. J Clin Oncol 2008; 26:1564; author reply 1565.
9. Compton P, Athanasos P, Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain 2003; 4:511-9.
10. Compton P, Miotto K, Elashoff D. Precipitated opioid withdrawal across acute physical dependence induction methods. Pharmacol Biochem Behav 2004; 77:263-8.
11. Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001; 93:155-63.
12. Schall U, Katta T, Pries E, et al. Pain perception of intravenous heroin users on maintenance therapy with levomethadone. Pharmacopsychiatry 1996; 29:176-9.
13. Ackerman WE, 3rd. Paroxysmal opioid-induced pain and hyperalgesia. J Ky Med Assoc 2006; 104:419-23.
14. Axelrod DJ, Reville B. Using methadone to treat opioid-induced hyperalgesia and refractory pain. J Opioid Manag 2007; 3:113-4.
15. Chung KS, Carson S, Glassman D, et al. Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia. Conn Med 2004; 68:547-9.
16. De Conno F, Caraceni A, Martini C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47:337-9.
17. Heger S, Maier C, Otter K, et al. Morphine induced allodynia in a child with brain tumour. BMJ 1999; 319:627-9.
18. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Care 2005; 22:291-4.
19. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59:313-6.
20. Sjogren P, Thunedborg LP, Christrup L, et al. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during longterm administration? Six case histories. Acta Anaesthesiol Scand 1998; 42:1070-5.
21. Lawlor P, Walker P, Bruera E, et al. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 1997; 13:356-361.
22. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7:43-8.
23. Cooper DW, Lindsay SL, Ryall DM, et al. Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine? Br J Anaesth 1997; 78:311-3.
24. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93:409-17.
25. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005; 103:147-55.
26. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106:49-57.
27. Troster A, Sittl R, Singler B, et al. Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans. Anesthesiology 2006; 105:1016-23.
28. Koppert W, Sittl R, Scheuber K, et al. Differential modulation of remifentanilinduced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003; 99:152-9.
29. Luginbuhl M, Gerber A, Schnider TW, et al. Modulation of remifentanilinduced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg 2003; 96:726-32, table of contents.
30. Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 2003; 97:810-15.
31. Koppert W, Dern SK, Sittl R, et al. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)- ketamine, and lidocaine. Anesthesiology 2001; 95:395-402.
32. Cortinez LI, Brandes V, Munoz HR, Guerrero ME, Mur M. No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia. Br J Anaesth 2001; 87:866-9.
33. Hansen EG, Duedahl TH, Romsing J, et al. Intra-operative remifentanil might influence pain levels in the immediate post-operative period after major abdominal surgery. Acta Anaesthesiol Scand 2005; 49:1464-70.
34. Lee LH, Irwin MG, Lui SK. Intraoperative remifentanil infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide. Anesthesiology 2005; 102:398-402.
35. Chu LF, Dairmont J, Zamora AK, et al. The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia. J Pain 2011; 12:108-15.
36. Andrews HL. The Effect of Opiates on the Pain Threshold in Post-Addicts. J Clin Invest 1943; 22:511-16.
37. Cepeda MS, Alvarez H, Morales O, et al. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004; 107:41-6.
38. Gan TJ, Ginsberg B, Glass PS, et al. Opioid-sparing effects of a lowdose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997; 87:1075-81.
39. Kayser V, Besson JM, Guilbaud G. Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats). Brain Res 1987; 414:155-7.
40. Shen KF, Crain SM. Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res 1994; 636:286-97.
41. Woolf CJ. Analgesia and hyperalgesia produced in the rat by intrathecal naloxone. Brain Res 1980; 189:593-7.
42. Woolf CJ. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res 1981; 209:491-5.
43. Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther 1988; 244:501-7.
44. Yaksh TL, Harty GJ, Onofrio BM. High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology; 64:590-7.
45. Hara N, Minami T, Okuda-Ashitaka E, et al. Characterization of nociceptin hyperalgesia and allodynia in conscious mice. Br J Pharmacol 1997; 121:401-8.
46. Sakurada T, Watanabe C, Okuda K, et al. Intrathecal high-dose morphine induces spinally-mediated behavioral responses through NMDA receptors. Brain Res Mol Brain Res 2002; 98:111-18.
47. Arts KS, Holmes BB, Fujimoto JM. Differential contribution of descending serotonergic and noradrenergic systems to central Tyr-D-Ala2-Gly- NMePhe4-Gly-ol5 (DAMGO) and morphine-induced antinociception in mice. J Pharmacol Exp Ther 1991; 256:890-6.
48. Colvin LA, Fallon MT. Opioid-induced hyperalgesia: a clinical challenge. Br J Anaesth 2010; 104:125-7.
49. Ram KC, Eisenberg E, Haddad M, et al. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain - new perspective of opioid-induced hyperalgesia. Pain 2008; 139:431-8.
50. Singler B, Troster A, Manering N, et al. Modulation of remifentanil-induced postinfusion hyperalgesia by propofol. Anesth Analg 2007; 104:1397-403, table of contents.
51. Grasshoff C, Gillessen T. Effects of propofol on N-methyl-D-aspartate receptor-mediated calcium increase in cultured rat cerebrocortical neurons. Eur J Anaesthesiol 2005; 22:467-70.
52. Kingston S, Mao L, Yang L, et al. Propofol inhibits phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in neurons. Anesthesiology 2006; 104:763-9.
53. De Kock M, Lavand'Homme P, Waterloos H. The short-lasting analgesia and long-term antihyperalgesic effect of intrathecal clonidine in patients undergoing colonic surgery. Anesth Analg 2005; 101:566-72, table of contents.
54. Davies MF, Haimor F, Lighthall G, et al. Dexmedetomidine fails to cause hyperalgesia after cessation of chronic administration. Anesth Analg 2003; 96:195-200, table of contents.